Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ibrutinib
Find trials that include:  Any drugs shown
Results 1-25 of 70 for your search:
Start Over
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Status: Enrolling by invitation
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR100955, NCI-2013-02262, 2012-004225-24, PCI-32765CAN3001, NCT01804686
Ibrutinib before and after Stem Cell Transplant in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A051301, NCI-2015-00668, BMT CTN 1201, NCT02443077
Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ACE-CL-006, NCI-2015-01966, NCT02477696
Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD)
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 12 and over
Trial IDs: PCYC-1140-IM, NCI-2017-00036, NCT02959944
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 60 and over
Trial IDs: PCYC-1141-CA, NCI-2017-00193, NCT02947347
A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BGB-3111-302, NCI-2017-00526, NCT03053440
Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1119-CA, NCI-2014-00660, PCI-32765 [Sponsor], NCT01962792
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1123-CA, NCI-2014-00826, NCT02077166
Ibrutinib with or without Methotrexate and Rituximab in Treating Patients with Refractory or Recurrent Primary or Secondary Central Nervous System Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-184, NCI-2014-02562, NCT02315326
Ibrutinib and Obinutuzumab in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and over
Trial IDs: GA101 + Ibrutinib, NCI-2015-02052, 141106, NCT02315768
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR106681, NCI-2017-00639, 2014-005191-28, PCI-32765LYM1002, NCT02329847
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to less than 80
Trial IDs: CC-122-CLL-001, NCI-2015-01973, NCT02406742
Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1138-CA, NCI-2015-01756, PCI-32765, NCT02548962
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1128-CA, NCI-2016-00449, NCT02599324
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MEDI4736-NHL-001, NCI-2016-00820, NCT02733042
Ibrutinib and Nivolumab in Treating Patients with Previously-Treated Metastatic Kidney Cancer
Status: Not yet active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCDCC#262, NCI-2016-01266, NCT02899078
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients with Relapsed or Refractory Grade 1-3A Follicular Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: LYMNHL0135, NCI-2016-01065, NCT02927964
A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCB 39110-206, NCI-2016-01883, NCT02760485
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients with Multiple Myeloma Ineligible for Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MC148A, NCI-2017-00006, NCT0315792
Combination Study of IPH2201 With Ibrutinib in Patients With Relapsed, Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IPH2201-202, NCI-2017-00298, NCT02557516
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Status: Enrolling by invitation
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1103-CA, NCI-2011-00986, PCI-32765, NCT01109069
Ibrutinib in Treating Patients with Relapsed Hairy Cell Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9268, NCI-2013-00826, 2012C0139, OSU-12200, NCT01981512, P131378, NCT01841723
Ibrutinib and Rituximab in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma or Older Patients with Newly Diagnosed Mantle Cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0090, NCI-2013-01304, NCT01880567
Ibrutinib with or without Rituximab in Treating Patients with Relapsed Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0703, NCI-2014-00989, NCI-2014-00843, NCT02007044
Ibrutinib after Intensive Induction in Treating Patients with Previously Untreated Mantle Cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 14H06, NCI-2014-01777, PCI-32765MCL2003, STU00098385, NCT02242097
Start Over